TITLE

Riluzole in the Treatment of Mood and Anxiety Disorders

AUTHOR(S)
Pittenger, Christopher; Coric, Vladimir; Banasr, Mounira; Bloch, Michael; Krystal, John H.; Sanacora, Gerard
PUB. DATE
July 2008
SOURCE
CNS Drugs;2008, Vol. 22 Issue 9, p761
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Recent advances implicate amino acid neurotransmission in the pathophysiology and treatment of mood and anxiety disorders. Riluzole, which is approved and marketed for the treatment of amyotrophic lateral sclerosis, is thought to be neuroprotective through its modulation of glutamatergic neurotransmission. Riluzole has multiple molecular actions in vitro; the two that have been documented to occur at physiologically realistic drug concentrations and are therefore most likely to be clinically relevant are inhibition of certain voltage-gated sodium channels, which can lead to reduced neurotransmitter release, and enhanced astrocytic uptake of extracellular glutamate. Although double-blind, placebo-controlled trials are lacking, several openlabel trials have suggested that riluzole, either as monotherapy or as augmentation of standard therapy, reduces symptoms of obsessive-compulsive disorder, unipolar and bipolar depression, and generalized anxiety disorder. In studies of psychiatrically ill patients conducted to date, the drug has been quite well tolerated; common adverse effects include nausea and sedation. Elevation of liver function tests is common and necessitates periodic monitoring, but has been without clinical consequence in studies conducted to date in psychiatric populations. Case reports suggest utility in other conditions, including trichotillomania and selfinjurious behaviour associated with borderline personality disorder. Riluzole may hold promise for the treatment of several psychiatric conditions, possibly through its ability to modulate pathologically dysregulated glutamate levels, and merits further investigation.
ACCESSION #
35282121

 

Related Articles

  • Effects of Subthalamic Nucleus Lesions and Stimulation upon Corticostriatal Afferents in the 6- Hydroxydopamine-Lesioned Rat. Walker, Ruth H.; Moore, Cindy; Davies, Georgia; Dirling, Lisa B.; Koch, Rick J.; Meshul, Charles K. // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Abnormalities of striatal glutamate neurotransmission may play a role in the pathophysiology of Parkinson's disease and may respond to neurosurgical interventions, specifically stimulation or lesioning of the subthalamic nucleus (STN). The major glutamatergic afferent pathways to the striatum...

  • An association analysis of synapse-associated protein 97 ( SAP97) gene in schizophrenia. Sato, Junko; Shimazu, Dai; Yamamoto, Naoki; Nishikawa, Toru // Journal of Neural Transmission;Sep2008, Vol. 115 Issue 9, p1355 

    SAP97 gene encodes the synaptic scaffolding PDZ proteins that interact with the l-alpha-amino-3-hydroxyl-5-methylisoxazole-4-propionate (AMPA), kainate and N-methyl- d-aspartate (NMDA) type glutamate receptors. Because the disturbed glutamate neurotransmission has been implicated in the...

  • Schizophrenia: Redox Regulation and Volume Neurotransmission. B�kkon, I.; Antal, I. // Current Neuropharmacology;Jun2011, Vol. 9 Issue 2, p289 

    No abstract available.

  • Enzymes in the glutamate-glutamine cycle in the anterior cingulate cortex in postmortem brain of subjects with autism. Shimmura, Chie; Suzuki, Katsuaki; Iwata, Yasuhide; Tsuchiya, Kenji J.; Ohno, Koji; Matsuzaki, Hideo; Iwata, Keiko; Kameno, Yosuke; Takahashi, Taro; Wakuda, Tomoyasu; Nakamura, Kazuhiko; Hashimoto, Kenji; Mori, Norio // Molecular Autism;2013, Vol. 4 Issue 1, p1 

    Background: Accumulating evidence suggests that dysfunction in the glutamatergic system may underlie the pathophysiology of autism. The anterior cingulate cortex (ACC) has been implicated in autism as well as in glutamatergic neurotransmission. We hypothesized that alterations in the...

  • Differences between unipolar and bipolar I depression in the quantitative analysis of glutamic acid decarboxylase-immunoreactive neuropil. Gos, Tomasz; Steiner, Johann; Bielau, Hendrik; Dobrowolny, Henrik; Günther, Karoline; Mawrin, Christian; Krzyżanowski, Maciej; Hauser, Roman; Brisch, Ralf; Bernstein, Hans-Gert; Jankowski, Zbigniew; Braun, Katharina; Bogerts, Bernhard // European Archives of Psychiatry & Clinical Neuroscience;Dec2012, Vol. 262 Issue 8, p647 

    Alterations in GABAergic neurotransmission are assumed to play a crucial role in the pathophysiology of mood disorders. Glutamic acid decarboxylase (GAD) is the key enzyme in GABA synthesis. This study aimed to differentiate between unipolar and bipolar I depression using quantitative evaluation...

  • Enhanced Glutamate Uptake into Synaptic Vesicles Fueled by Vesicle-generated ATP from Phosphoenolpyruvate and ADP. Takeda, Kouji; Ueda, Tetsufumi // Neurochemical Research;Dec2012, Vol. 37 Issue 12, p2731 

    Glycolytic ATP synthesis by synaptic vesicles provides an efficient mechanism for fueling vesicular loading of the neurotransmitter glutamate. This is achieved in part by vesicle-bound pyruvate kinase. However, we have found that vesicular glutamate uptake, in the presence of the pyruvate kinase...

  • Increased Hippocampal Glutamate and Volumetric Deficits in Unmedicated Patients With Schizophrenia. Kraguljac, Nina V.; White, David M.; Reid, Meredith A.; Lahti, Adrienne C. // JAMA Psychiatry;Dec2013, Vol. 70 Issue 12, p1294 

    IMPORTANCE Alterations in glutamatergic neurotransmission have been postulated to be a key pathophysiologic mechanism in schizophrenia. OBJECTIVE To evaluate hippocampal volumetric measures and neurometabolites in unmedicated patients with schizophrenia and the correlations between these...

  • Effects of Subthalamic Nucleus Lesions and Stimulation upon Corticostriatal Afferents in the 6- Hydroxydopamine-Lesioned Rat. Walker, Ruth H.; Moore, Cindy; Davies, Georgia; Dirling, Lisa B.; Koch, Rick J.; Meshul, Charles K. // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Abnormalities of striatal glutamate neurotransmission may play a role in the pathophysiology of Parkinson's disease and may respond to neurosurgical interventions, specifically stimulation or lesioning of the subthalamic nucleus (STN). The major glutamatergic afferent pathways to the striatum...

  • No Association Between GRM3 and Japanese Methamphetamine-Induced Psychosis. Tsunoka, Tomoko; Kishi, Taro; Ikeda, Masashi; Kitajima, Tsuyoshi; Yamanouchi, Yoshio; Kinoshita, Yoko; Kawashima, Kunihiro; Okochi, Tomo; Okumura, Takenori; Inada, Toshiya; Ujike, Hiroshi; Yamada, Mitsuhiko; Uchimura, Naohisa; Sora, Ichiro; Iyo, Masaomi; Ozaki, Norio; Iwata, Nakao // Current Neuropharmacology;Mar2011, Vol. 9 Issue 1, p160 

    No abstract available.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics